<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109989</url>
  </required_header>
  <id_info>
    <org_study_id>MEMIC-5083</org_study_id>
    <nct_id>NCT04109989</nct_id>
  </id_info>
  <brief_title>Clinical Assessment - HominisTM Surgical System</brief_title>
  <official_title>Clinical Assessment - HominisTM Surgical System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memic Innovative Surgery</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memic Innovative Surgery</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical research study designed to assess the HominisTM Surgical System in gynecological
      procedures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of conversion</measure>
    <time_frame>Intra Operative</time_frame>
    <description>Rate of conversion to open or laparoscopic approach</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-operative &amp; post-operative procedural outcomes</measure>
    <time_frame>Intra-operative and six weeks post procedure</time_frame>
    <description>Intra-operative &amp; post-operative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-operative &amp; post-operative procedural outcomes</measure>
    <time_frame>Intra-operative &amp; six weeks post procedure</time_frame>
    <description>adverse events (AE and SAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-operative &amp; post-operative procedural outcomes</measure>
    <time_frame>Intra-operative &amp; six weeks post procedure</time_frame>
    <description>Bladder injury rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-operative &amp; post-operative procedural outcomes</measure>
    <time_frame>Intra-operative &amp; six weeks post procedure</time_frame>
    <description>Rectal injury rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-operative procedural outcomes</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Operative time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-operative &amp; post-operative procedural outcomes</measure>
    <time_frame>Intra-operative &amp; six weeks post procedure</time_frame>
    <description>Transfusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-operative procedural outcomes</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Conversion rate (to laparotomy, laparoscopy, other ports used in addition to vaginal and umbilical port).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-operative &amp; post-operative procedural outcomes</measure>
    <time_frame>Intra-operative &amp; six weeks post procedure</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative procedural outcomes</measure>
    <time_frame>Six weeks post procedure</time_frame>
    <description>Length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative procedural outcomes</measure>
    <time_frame>Six weeks post procedure</time_frame>
    <description>Re-admission rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative procedural outcomes</measure>
    <time_frame>Six weeks post procedure</time_frame>
    <description>Re-operation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal tissue healing</measure>
    <time_frame>Six weeks post procedure</time_frame>
    <description>Vaginal tissue healing will be assessed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hysterectomy</condition>
  <arm_group>
    <arm_group_label>HominisTM Surgical System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gynecological surgical procedure will be performed with the HominisTM Surgical System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HominisTM Surgical System</intervention_name>
    <description>Trans-vaginal gynecological procedures</description>
    <arm_group_label>HominisTM Surgical System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female above 18 years of age inclusive.

          2. Able to provide written informed consent.

          3. Eligible for Total Transvaginal Laparoscopic Hysterectomy with Salpingo-Oophorectomy
             or Transvaginal Laparoscopic Hysterectomy with Salpingectomy and have an appropriate
             indication to go through this surgery.

          4. Willing to undergo laparoscopic transvaginal procedure by Memic HominisTM Surgical
             System.

          5. Fit for robotic-assisted transvaginal surgery based on surgeon discretion.

          6. Can undergo general anesthesia per anesthesiologist assessment.

        Exclusion Criteria:

          1. Women with anatomical hazard for laparoscopy and/or vaginal and/or pouch of Douglas
             access (such as diagnosis of Crohn's disease, active Pelvic inflammatory disease
             (PID), active diverticulitis, sever peritoneal adhesions, frozen pelvis, obliterated
             vagina or sever recto-vaginal endometriosis).

          2. Women after pelvic radiation.

          3. Women diagnosed with active intra-abdominal malignancy.

          4. Women with general condition or illness incompatible for surgery.

          5. Women who are pregnant.

          6. Unwillingness or inability to follow the procedures outlined in the protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The device is intended for Vaginal procedures</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Limor Kuznits, B.Sc</last_name>
    <phone>+972-54-630-20-12</phone>
    <email>Limor@memicmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imelda Hospital</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Baekelandt, Dr</last_name>
      <phone>+32 499 47 1371</phone>
      <email>Jan.Baekelandt@imelda.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Hospital</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omer Mor, Dr.</last_name>
      <phone>054-648-6414</phone>
      <email>omermor23@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>February 16, 2020</last_update_submitted>
  <last_update_submitted_qc>February 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

